Last reviewed · How we verify
NCT01916187
Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma
Phase 1 trial testing Imetelstat in Neuroblastoma. Withdrawn.
22 November 2013
Quick facts
| Lead sponsor | NCIC Clinical Trials Group |
|---|---|
| Phase | Phase 1 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Start date | 30 July 2013 |
| Primary completion | 22 November 2013 |
| Estimated completion | 16 January 2014 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Imetelstat (IMETELSTAT) — full drug profile →
Conditions studied
- Neuroblastoma — all drugs for Neuroblastoma →
Sponsor
NCIC Clinical Trials Group
Who can join
Adults 18 Months to 18, any sex, with Neuroblastoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to determine the best dose of imetelstat when given alone for patients with neuroblastoma and also when given in combination with 13-cis-retinoic acid.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Chemoprevention of neuroblastoma: progress and promise beyond uncertainties.
Aravindan N, Natarajan M, Somasundaram DB, Aravindan S. · · 2023 · cited 1× · PMID 38249515 · DOI 10.20517/2394-4722.2022.40
Verify or expand the search:
- PubMed search for NCT01916187
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Imetelstat
Trials testing the same drug.
- NCT06247787 — A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS · Phase 1 · recruiting
- NCT04576156 — A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosi · Phase 3 · active not recruiting
- NCT01731951 — Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis · Phase 2 · completed
- NCT05937568 — Expanded Access for Treatment With Imetelstat · approved for marketing
Other recruiting trials for Neuroblastoma
Currently open trials in the same condition.
- NCT07399821 — An Imaging Study of Anti-GD2-800CW in Patients With Neuroblastoma · Phase 1, PHASE2 · recruiting
- NCT06995872 — Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refra · Phase 1 · recruiting
- NCT06942039 — Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation · EARLY_PHASE1 · recruiting
- NCT07067346 — Safety & Efficacy of IR-101 in Relapsed/Refractory Neuroblastoma · EARLY_PHASE1 · recruiting
- NCT07027748 — Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or R · Phase 1 · recruiting
Other NCIC Clinical Trials Group trials
Trials by the same sponsor.
- NCT01830621 — BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Pretreated Advanced Colorectal Carcinoma · Phase 3 · completed
- NCT01652144 — A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma · Phase 2 · completed
- NCT01627054 — A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia · Phase 2 · completed
- NCT01486368 — A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma · Phase 2 · completed
- NCT01331083 — A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01916187 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by NCIC Clinical Trials Group
- Last refreshed: 21 September 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01916187.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing